We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Feedback Plc | LSE:FDBK | London | Ordinary Share | GB00BJN59X09 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.50 | -2.74% | 17.75 | 17.00 | 18.50 | 18.25 | 17.75 | 18.25 | 90,680 | 08:49:32 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Electronic Computers | 1.03M | -2.92M | -0.0666 | -2.67 | 8M |
Date | Subject | Author | Discuss |
---|---|---|---|
16/10/2024 08:28 | I will have to re-read it though ! This bit is hidden in there: “ the more activity delivered and diversions achieved the more an ICB will be reimbursed” So the money appears to FOLLOW the activity. ie. Feedback provide the service and then get paid later, depending on no. of patients. That would be very good for securing repeat revenues IF the throughput is sufficient, but it appears to require up front spend from feedback. Existing contracts presumably will be moved or renewed on that basis, which takes them out of annual renewal capital spend and potential risk of being cut. No FDBK spend involved there hopefully. Although this new funding runs out in March 2025. If these new fangled contracts with a new ICB or trust don’t have a capital element, then Feedback is going to have to fund them with its own capital initially. The contracts may have zero committed value, with just a per patient clause. So the risk is all transferred to Feedback and success depends on whether clinicians buy into it or not. Lots of words in the RNS, but not the ones that matter to shareholders. I suspect the next step may be a series of announcements of “contractsR The implementation is clearly not going to fund itself. | yump | |
16/10/2024 07:37 | yump - Thanks - So maybe is the operative word. | pugugly | |
16/10/2024 06:40 | Sort of good news - perhaps. So ring fenced and diverted capital budgets are supposedly an obstacle. Now there is a fund in revenue spend for diverting patients away from normal outpatient process. That doesn’t answer the question of how many trusts are interested but stuck with the capital spend problem. That is what I want to know. We have never been told that crucial information. It also doesn’t cover the overall process of implementing Bleepa in a location, because its per-patient funding. Can a trust get advance funding for a prospective number of patients, or does FDBK have to carry the implementaion spend/effort before any cash is forthcoming - and that depends on patient flow. So is there a contract committment from a trust ? Without it FDBK will be like a charity and so will shareholders. The fact that they need an implementation partner makes me think they have been useless in getting even committment in principle from more tham a handful of trusts. | yump | |
16/10/2024 06:40 | Can anyone explain today's rns in plain language? Sounds good but? | pugugly | |
11/10/2024 18:45 | No comment | yump | |
11/10/2024 17:55 | yump - Nice one - With inside knowledge I understand the registered name of your new enterprise may be "South Sea Bubbles" | pugugly | |
11/10/2024 17:49 | Would anyone like to know the total addressable market for my new social media add-on ? I’m afraid I will only be able to divulge information like that to investors putting at least £5000 up. (Small print: There is no guarantee that anyone I try to address will listen to anything) | yump | |
11/10/2024 16:53 | LR2, total addressable market = bullsh1t. | ducatiman | |
10/10/2024 15:12 | Anyone noticed the changes to the Investors page of Feedback Medical? The total addressable markets information is a good reminder. | lr2 | |
10/10/2024 14:57 | Thanks LR2! I notice Sectra and Palantir are in that list. Both companies have been mentioned in this thread. Sectra in particular is notable since it's the PACs system used in the NCA. Bleepa obviously complements that PACS system. Now how much of the £2B will be set aside for Feedback Medical? About time something was awarded by Guys. After all it is the home of Feedback I seem to recall. | ged5 | |
10/10/2024 12:07 | Anybody got the will to investigate this? II.1.7) Total value of the procurement (excluding VAT) Value excluding VAT: £2,000,000,000 V.2.3) Name and address of the contractor Feedback Medical Limited London EC4Y 0DT 81 contractors named. Feedback are No 56. | lr2 | |
09/10/2024 18:45 | Nice one - | pugugly | |
09/10/2024 18:37 | Pugugly I’ve already got some shares so you could trust me to bang on doors until my knuckles are sore, although I am rather partial to nice conference lunches, especially if they are overseas and I do quite like speaking in front of an audience that is partially asleep ;-) | yump | |
09/10/2024 18:25 | Market cap £5.5M - Maybe should have a quick whip-round - Take over the company and hire some very good technical sales people. YUMP to be sales director? That is after DD the technology proves to be as good as claimed? | pugugly | |
09/10/2024 17:33 | Still stealing £3k a week for talking bullsh1te. Still not a shareholder. Suck it up shareholders. Him and his sidekick will hang in there as long as they can. | ducatiman | |
25/9/2024 17:00 | I just can’t believe how this numpty is still employed on £3k a week. Add to that his sidekick Anel. On a tad less. Any “proper” business would have ditched them long ago. Clear your desk time. AIM at its worst. Allowing huge incompetence and paying dearly for it. Laughable. | ducatiman | |
24/9/2024 16:47 | Released a few hours ago. Feedback Collaboration Agreement in Primary Care - 24/09/24 | lr2 | |
23/9/2024 16:44 | I haven’t got the time to look back over many years of investing, but I’ve got a feeling that tiny businesses announcing “collaboration ie. The product just does not sell enough to make a viable business and revenue coming from any joint agreement has a margin that isn’t worth getting out of bed for. | yump | |
23/9/2024 16:32 | Its like they’ve read a book on how to expand your business, before they’ve actually got anything significant to expand. Unlike some AIM companies who use shareholders money for working capital to fund contracts, this lot are just using it for experimental marketing, just like a lot of others with big ideas and nothing else. Wouldn’t it be great if all directors had to have a go at making money before they can join a BOD. Give them a wad and if they don’t come with a profit in 3 months, they don’t get to be a director. | yump | |
20/9/2024 16:14 | Ditto Ged. Just so glad I reduced significantly. What price the next placing? | ducatiman | |
20/9/2024 12:22 | This fella is very good at putting out announcements that might be believable if he answered all questions in presentaions and was actually a shareholder. India partnership "likely initially" UK, UAE, SA partnership "Resell each other's products" Do FDBK sell much? Unknown partner "intention to explore creating a solution" "The parties intend to pilot the solution" All these maybes - could be a play! Beginning to doubt my sanity at actually owning some shares in this lot. | ged5 | |
19/9/2024 13:16 | Getting exciting, a collaboration that might lead to a pilot. You couldn’t make it up. | ducatiman | |
19/9/2024 06:39 | Oh look, a new development idea before they’ve got any decent repeat revenue and contracts from the existing product to fund it. Bonus for TO for that and another big placing to fund the amazing development please. | yump | |
18/9/2024 13:57 | Knowing Amazon they would allow adverts showing the pager brand as being from Taiwan, even if it was Russian. Seeing as a load of bogus brands fill the sponsored spaces at the top of their pages and they allow union jacks and “UK business” to be placed on product listings from Wintangwon province. | yump |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions